These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
4 files

Metabolomics Analysis Reveals Both Plant Variety and Choice of Hormone Treatment Modulate Vinca Alkaloid Production in Catharanthus Roseus.

revised on 22.04.2020, 04:58 and posted on 22.04.2020, 13:09 by Valerie Fraser, Benjamin Philmus, Molly Megraw

The medicinal plant Catharanthus roseusproduces numerous secondary metabolites of interest for the treatment of many diseases—most notably for the terpene indole alkaloid (TIA) vinblastine, which is used in the treatment of leukemia and Hodgkin’s lymphoma. Historically, methyl jasmonate (MeJA) has been used to induce TIA production, but in the past, this has only been investigated in either whole seedlings, cell culture, or hairy root culture. In this work, we investigate the induction capabilities of MeJA and ethylene, a different phytohormone, in both the shoots and roots of two varieties of C. roseus. Using LCMS and RT-qPCR, we demonstrate the importance of variety selection, as we observe markedly different induction patterns of important TIA precursor compounds. Additionally, both phytohormone choice and concentration have significant effects on TIA biosynthesis. Finally, our study suggests that several early-induction pathway steps as well as pathway-specific genes are likely to be transcriptionally regulated. Our findings highlight the need for a complete set of ’omics resources in commonly used C. roseus varieties.


Medical Research Foundation of Oregon (2018-1954)


Email Address of Submitting Author


Oregon State University


United States

ORCID For Submitting Author


Declaration of Conflict of Interest


Version Notes

Revision contains updated cited references, new figures, altered text and increased discussion.